News - Page 94 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Psilera Receives First Patent Allowance for Transdermal Patch Formulations

Psilera Receives First Patent Allowance for Transdermal Patch Formulations

Post published:September 14, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Post published:September 14, 2022
Post category:Press Release

Read more about the article Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Post published:September 14, 2022
Post category:Press Release

Read more about the article Sunstone Therapies Collaborates with MAPS to Conduct Clinical Trial of MDMA-Assisted Therapy for PTSD

Sunstone Therapies Collaborates with MAPS to Conduct Clinical Trial of MDMA-Assisted Therapy for PTSD

Post published:September 14, 2022
Post category:Press Release

Read more about the article Small Pharma Enters Into Automatic Share Purchase Plan

Small Pharma Enters Into Automatic Share Purchase Plan

Post published:September 13, 2022
Post category:Press Release

Read more about the article Numinus provides update on acquisition integration and announces new client financing options

Numinus provides update on acquisition integration and announces new client financing options

Post published:September 13, 2022
Post category:Press Release

Read more about the article Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Post published:September 13, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Post published:September 13, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Post published:September 12, 2022
Post category:Psychedelic Bulletin

Read more about the article Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home

Post published:September 12, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.